- Blood plasma makes up around 55% of blood and can be separated and used to create life-saving therapies. It is in high demand globally. - New technologies like PrIME Biologics' membrane electrophoresis allow for more rapid and higher-yield plasma separation than traditional methods. - Locally sourced plasma is preferable to imported plasma for regions like Southeast Asia, as locals have immunity to tropical diseases and it reduces costs. - Xeraya Capital is working with PrIME Biologics to commercialize new plasma separation technologies to better meet regional healthcare needs.

1. PLASMA INDUSTRY
Market Potential & New Technologies
For more info, contact us: xeraya@xeraya.com
Follow us: @xerayacapital
www.xeraya.com

2. WHAT IS PLASMA?
Largest component of your
blood, making up about 55%
of overall content.
Isolated, it is a light yellow
liquid.
Along with water, plasma
carries salts and enzymes.
Source: https://www.urmc.rochester.edu/encyclopedia/

3. Blood plasma is separated by
spinning a tube of fresh blood
containing an anticoagulant in a
centrifuge until the blood cells fall to
the bottom of the tube.
The blood plasma is then poured or
drawn off.
Source: https://www.redcrossblood.org/donate-blood/how-to-donate/types-of-blood-donations/blood-components.html
HOW IS IT OBTAINED?

4. WHAT IS PLASMA GOOD FOR?
Plasma derivatives can simply
SAVE LIVES.
Plasma that has been processed
contains major types of proteins
(namely Albumin and Globulins).
These are useful in medical
emergencies (burns, shocks,
trauma, etc.). Derivatives are used
to create therapies for rare chronic
conditions, such as autoimmune
disorders and hemophilia.
Source: https://www.urmc.rochester.edu/encyclopedia/

5. MAJOR BLOOD plasma products
Source: https://www.mt-pharma.co.jp

6. USE OF BLOOD PLASMA COMPONENTS
Plasma Component Reasons for Use
Factor VIII hemophilia A
Factor IX hemophilia B
Factor X congenital deficiency
Factor XIII congenital deficiency
PCC complex
anticoagulant overdose
factor II and factor X if Factor X not available deficiencies liver disease
Immunoglobulin
passive prophylaxis
immune deficiency disorders
some types of immune thrombocytopenic purpura
Guillain–Barré syndrome
Polyneuropathies
Antithrombin III
congenital deficiency
disseminated intravascular coagulation
Fibrinogen
congenital deficiency
massive hemorrhage
C1 inhibitor hereditary angioedema
Albumin
Hypoalbuminemia
Ascites
Restoring of blood volume in trauma, burns and surgery patients
Alpha-I-antitrypsin
hereditary deficiencies
emphysema and COPD cirrhosis

7. MARKET VALUE FOR BLOOD PLASMA
North America
$8.2 billion 2016
$11.1 billion 2021 (est.)
6.3% CAGR
Source: https://www.prnewswire.com/news-releases/global-markets-for-blood-plasma-products-300497352.html
Asia Pacific
$4.4 billion 2016
$6.1 billion 2021 (est.)
7.1% CAGR

8. Therapeutic PLASMA DEMAND
For the last 30 years, there has
been a continual increase in the
need for therapeutic plasma
products, such as coagulation
factors, immunoglobulin G (IgG)
and albumin at the global level.
*These products include coagulation factors VIII and
factor IX; human normal immunoglobulin G; anti-D,
antitetanus and antirabies immunoglobulins.
Source: ISBT Science Series 2014: New approaches for manufacturing plasma derivatives

9. BLOOD PLASMA POTENTIAL
WORLDWIDE
21.6 million liters
recovered each
year
Source: WHO Report 2015 - Improving access to safe blood
products through local production and technology transfer in
blood establishments
Plasma
Derivatives
value up to US
$5.8 billion
*Current value:
$70 - $110 per litre of plasma
>$400 per litre of derivatives

10. MARKET FORECAST:
PLASMA DERIVATIVES
Source: http://www.kitv.com/story/38199042/blood-plasma-derivatives-
market-with-a-cagr-of-approximately-752-usher-in-a-period-of-
transformation-by-type-albumin-anti-thrombin-iii-intravenous
By 2023, Market Research
Future estimates annual market
value of up to US$ 58.2 billion,
with a CAGR of 7.52% during
the forecast period

11. CURRENT USE WITHIN US & EU
Most of the plasma fractionated in
the world is collected in the United
States or Europe.
A large proportion of fractionated
products is used in the
industrialized world, given the
potential of plasma therapy within
the market.

12. Blood CENTERS & plasma COLLECTED
ex: southeast asia
The rise in blood collections to meet therapeutic
demands for red blood cells in the region drive several
countries to consider using excess local plasma to
prepare fractionated plasma products.
72
123
157 200
168
Vietnam Malaysia Thailand Philippines Indonesia
Stand-alone Hospital-based
Number of Blood Centers
*
Total 72
124
170
375
71
111
148
164
407
32
Philippines Malaysia Thailand Vietnam Indonesia
Estimated Amount of Plasma Collected (‘000 L)

13. CURRENT TECHNOLOGY TO
SEPARATE PLASMA PRODUCTS
Cohn Method (dev. WWII)
This process is also known as cold
ethanol fractionation as it involves
gradually increasing the
concentration of ethanol in the
solution at 5°C and 3°C. The Cohn
Process exploits differences in
properties of the various plasma
proteins, specifically, the high
solubility and low pI of albumin.
Chromatography
Chromatographic albumin
processing as an alternative to the
Cohn Process emerged in the early
1980s, however, it was not widely
adopted until later due to the
inadequate availability of large
scale chromatography equipment
1946
1983

14. PRIME: NEW TECHNOLOGY TO
SEPARATE PLASMA PRODUCTS
A large-scale preparative
electrophoresis technology across
membranes of controlled porosity,
previously known as ‘Gradiflow’ and
now developed by PrIME Biologics
(Singapore), was presented as a
means to provide rapid, high-
resolution purification of proteins
from complex mixtures.
Source: ISBT Science Series 2014: New approaches for manufacturing plasma derivatives

15. PRIME: NEW TECHNOLOGY TO
SEPARATE PLASMA PRODUCTS
Proteins in the sample stream are purified in a
separation cartridge comprising a restriction
membrane and separation membrane.
Voltage applied across the system facilitates
the movement of charged proteins.
Proteins are partitioned through a separation
membrane system based on differences in
sizes and charges at a given pH.
Source: ISBT Science Series 2014: New approaches for manufacturing plasma derivatives

16. PRIME: NEW TECHNOLOGY BENEFITS
High separation range: from 10 to 1500 kDa
Can be used to remove contaminants (viruses and prions)
Rapid purification of proteins, with 2x yield vs
conventional separation techniques
For plasma fractionation, the technology can be combined
with more conventional separation technologies, like
chromatography, to further purify proteins

17. LOCAL VS IMPORTED BLOOD PLASMA
North America: Lower immunity towards
tropical diseases such as dengue & malaria
- Storage, packaging & transportation costs
- Export & cross-border procedures
Southeast Asia: Developed overall
immunity towards tropical diseases
such as dengue & malaria
- Lower cost of transportation
- Better suited plasma
If you’re from Malaysia, it is better to use locally derived blood
plasma for therapy. Regional trend suggests the locals have
developed a certain degree of immunity towards local-borne
‘tropical’ diseases such as dengue and malaria. In addition, it would
help save to save various storage & transit costs.
- Cost of transportation & care
- Security & screening

18. CONCLUSION
• There should be increased awareness on the importance of
blood plasma, and the benefits it has to offer to the healthcare
industry;
• The World Health Organization encourages the use of locally
derived blood plasma, as opposed to importing;
• With the emergence of new technologies, it is hoped that we
can cater low to medium capacity demand with twice the
yield for blood plasma and derivatives at a lower CAPEX,
especially in developing and less-developed regions.

19. Xeraya & prime biologics
Xeraya Capital has taken a bold step by investing in emerging
technologies, particularly in working with PrIME Biologics to
explore the potential commercialization of blood plasma
derivatives that caters to current regional demand.

20. By xeraya capital
For more info, contact us: xeraya@xeraya.com
Follow us: @xerayacapital
www.xeraya.com